Caricamento quotazioni...
Previsioni
| Acquista |
17 |
| Mantieni |
15 |
| Vendi |
4 |
Discussioni nella community
- Ticker
Generales Problem bei Aktien wird immer nur 1 zufälliger Ticker angezeigt. Mit Pech ist der Ticker veraltet oder inaktiv. Beispiel AstraZeneca (ISIN: GB0009895292): Statt des seit fast einem Jahr…
M Mars V in Terminal
4 0 - Novo Nordisk
Moin, Umfrage: Wer hatte alles die Faxen dicke und hat abgestoßen und wer hat die “Chance” genutzt und seinen Buy-In gedrückt? 😅 🏃♂️💨💨💨 ...raus da.... 💰💸 ...all in... 🫷...stehe (noch) an der…
s sanzen I in Schnack
3 20
Notizie Vai al feed delle notizie
AstraZeneca beats expectations after strong quarter in cancer drugs
AstraZeneca reported third-quarter revenue up 7% to about $16.2 billion and a group net profit of roughly $3.1 billion (around +25%). Adjusted earnings per share beat analysts’ expectations; the cancer drugs division grew 17% to just under $7.8 billion and accounted for almost half of sales, while revenue in the cardiovascular, renal and metabolism area fell by about one fifth to $2.6 billion. CEO Pascal Soriot confirmed the targets for 2026 and 2030; for the current year, currency‑adjusted sales growth in the mid‑to‑high single digits and a low‑double‑digit increase in adjusted earnings per share are expected. The shares jumped sharply after the results. » Altro su finanzen.net
Astrazeneca beats expectations with strong Q3 thanks to cancer drugs
Astrazeneca reports a 7% rise in third-quarter revenue to about $16.2 billion and a 25% increase in net income to $3.1 billion, both above market expectations. Revenue was driven by cancer drugs, whose sales rose 17% to nearly $7.8 billion, making up almost half of group sales, while cardiovascular, renal and metabolic medicines fell by around one fifth. CEO Pascal Soriot reaffirms targets for 2026 and 2030; analysts at Bernstein, Jefferies and UBS confirm or raise buy ratings and lift price targets. The stock jumped sharply, topping the 200-day moving average; the dividend yield is around 2.0%. » Altro su deraktionaer.de
AstraZeneca surprises with strong revenue and profit growth
AstraZeneca reported a 7% rise in third-quarter revenue to about $16.2 billion and a roughly 25% increase in net profit to $3.1 billion. Sales of cancer drugs rose 17% to just under $7.8 billion, while revenues in the cardiovascular, renal and metabolic segment fell by about one-fifth to $2.6 billion. CEO Pascal Soriot said the company is on track to meet its 2026 and 2030 targets; for 2024 AstraZeneca expects currency-adjusted mid- to high-single-digit revenue growth and low-double-digit growth in adjusted earnings per share. In London the stock rose as much as about 2.9% and traded at £134.36. » Altro su finanzen.net
AstraZeneca: EU approval for Enhertu in early HER2-positive breast cancer
The EU Commission has approved Enhertu from AstraZeneca and Daiichi Sankyo as monotherapy for patients with residual disease after surgically removed HER2‑positive early-stage breast cancer. The approval, the first for Enhertu with curative intent in the early-stage setting, is based on Phase III data that reduced the risk of recurrence or death. The AstraZeneca stock showed only a slight reaction to the news. » Altro su finanzen.net
Astrazeneca and Oracle enter AI partnership to accelerate clinical research
Astrazeneca has agreed with Oracle on a collaboration that links Astrazeneca's scientific expertise with Oracle's real-world data, cloud and AI capabilities. The aim is to evaluate selected use cases, make clinical trials more efficient, generate evidence across the entire drug lifecycle and improve patient care. The cooperation is non-binding and is intended to help identify patients earlier and increase trial success rates. » Altro su deraktionaer.de
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 15,38 Mld | 6,41% |
| Utile lordo | 12,86 Mld | 7,32% |
| Utile netto | 2,51 Mld | 2,33% |
| EBITDA | 5,16 Mld | 4,20% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 249,23 Mld € |
Numero di azioni | 1,55 Mld |
Massimo/minimo a 52 settimane | 166,30 € - 111,00 € |
Rendimento da dividendo | 1,66% |
Dividendi TTM | 2,77 € |
Beta | 0,23 |
Rapporto P/E | 25,60 |
Rapporto PEG | 1,55 |
Rapporto P/B | 5,50 |
Rapporto P/S | 4,53 |
Profilo aziendale
AstraZeneca PLC, una società biofarmaceutica, si concentra sulla scoperta, lo sviluppo, la produzione e la commercializzazione di farmaci da prescrizione. I suoi prodotti commercializzati includono Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso e Zoladex per l'oncologia; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern e Xigduo/Xigduo XR per le malattie cardiovascolari, renali e metaboliche; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort e Tudorza/Eklira/Bretaris per le malattie respiratorie e l'immunologia; e Andexxa/Ondexxya, Kanuma, Soliris, Strensiq e Ultomiris per le malattie rare. I prodotti commercializzati dalla società comprendono anche Synagis per il virus respiratorio sinciziale; Fluenz Tetra/FluMist Quadrivalent per l'influenza; Seroquel IR/Seroquel XR per la schizofrenia e il disturbo bipolare; Nexium e Losec/Prilosec per la gastroenterologia; e Vaxzevria ed Evusheld per la covid-19. La società si rivolge a medici di medicina generale e specialisti tramite distributori e uffici di rappresentanza locali nel Regno Unito, nel resto d'Europa, nelle Americhe, in Asia, in Africa e in Australasia. Ha un accordo di collaborazione con Regeneron Pharmaceuticals, Inc. per ricercare, sviluppare e commercializzare farmaci a piccola molecola per l'obesità; con Neurimmune AG per sviluppare e commercializzare NI006; con Ionis Pharmaceuticals, Inc. per sviluppare eplontersen, una terapia antisenso mirata al fegato in fase III di sviluppo per il trattamento dell'amiloidosi da transtiretina; con Proteros Biostructures GmbH per scoprire congiuntamente nuove piccole molecole per il trattamento dei tumori ematologici; e con Sierra Oncology, Inc. per sviluppare e commercializzare AZD5153. La società era in precedenza nota come Zeneca Group PLC e ha cambiato nome in AstraZeneca PLC nell'aprile 1999. AstraZeneca PLC è stata costituita nel 1992 ed ha sede a Cambridge, nel Regno Unito.
| Nome | AstraZeneca |
| CEO | Pascal Claude Roland Soriot |
| Sede centrale | Cambridge,
Regno Unito |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 21/05/1993 |
| Dipendenti | 94.300 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Pnk | AZNCF |
London Stock Exchange | AZN.L |
XETRA | ZEG.DE |
Sto | AZN.ST |
Frankfurt | ZEG.F |
Düsseldorf | ZEG.DU |
Hamburg | ZEG.HM |
London | AZN.L |
Stockholm | AZN.ST |
SIX | AZN.SW |
München | ZEG.MU |